消化

订阅

MedSci主页 / 所有栏目 / 消化

Cell Metab：棕色脂肪有助于治疗肥胖症

2013-02-17 CELL METAB 中国新闻网

棕色脂肪治疗肥胖症Sprott加拿大科学家
关注

　　加拿大渥太华大学科学家使用肌肉干细胞，在实验室老鼠身上制造出可以燃烧卡路里的棕色脂肪，有助于治疗加拿大人日渐普遍的肥胖症。 　　据介绍，棕色脂肪是哺乳类动物身体制造的两种脂肪之一。棕色脂肪与白色脂肪相比，属于好脂肪，因为它属于发热组织，能够燃烧掉存在白色脂肪中的卡路里。棕色脂肪多在新生婴儿及冬眠动物体内发现。 　　渥太华大学附属机构、渥太华医院研究所科学家使用成年老鼠的肌肉干细胞制成复合物


　　加拿大渥太华大学科学家使用肌肉干细胞，在实验室老鼠身上制造出可以燃烧卡路里的棕色脂肪，有助于治疗加拿大人日渐普遍的肥胖症。

　　据介绍，棕色脂肪是哺乳类动物身体制造的两种脂肪之一。棕色脂肪与白色脂肪相比，属于好脂肪，因为它属于发热组织，能够燃烧掉存在白色脂肪中的卡路里。棕色脂肪多在新生婴儿及冬眠动物体内发现。

　　渥太华大学附属机构、渥太华医院研究所科学家使用成年老鼠的肌肉干细胞制成复合物，然后将复合物注射入实验室老鼠体内，导致实验老鼠产生棕色脂肪，体重迅速下降。

　　渥太华医院研究所再生医学计划暨Sprott干细胞研究中心主任鲁德尼基(Michael Rudnicki)表示，令人惊讶的是，在经过4个月观察后，经注射复合物的实验老鼠，体重持续减轻。

　　鲁德尼基指出，此一发现使得科学家们未来能够再进一步利用这种好脂肪，治疗所有与肥胖有关的病症。

　　根据加拿大公共卫生署的资料，迄至2007年，每4个加拿大人中就有1人属于肥胖，且有很高比率的人是超重。同一年，加拿大人民的肥胖情形被世界卫生组织列为全球第35，在超过15岁的加拿大人中，61.1%体重超重。

　　渥太华大学科学家的上述报告刊载于《细胞代谢》(Cell Metabolism)期刊，但使用这种新方法治疗肥胖症，可能还需要相当一段时间。


Summary
Brown adipose tissue (BAT) is an energy-dispensing thermogenic tissue that plays an important role in balancing energy metabolism. Lineage-tracing experiments indicate that brown adipocytes are derived from myogenic progenitors during embryonic development. However, adult skeletal muscle stem cells (satellite cells) have long been considered uniformly determined toward the myogenic lineage. Here, we report that adult satellite cells give rise to brown adipocytes and that microRNA-133 regulates the choice between myogenic and brown adipose determination by targeting the 3′UTR of Prdm16. Antagonism of microRNA-133 during muscle regeneration increases uncoupled respiration, glucose uptake, and thermogenesis in local treated muscle and augments whole-body energy expenditure, improves glucose tolerance, and impedes the development of diet-induced obesity. Finally, we demonstrate that miR-133 levels are downregulated in mice exposed to cold, resulting in de novo generation of satellite cell-derived brown adipocytes. Therefore, microRNA-133 represents an important therapeutic target for the treatment of obesity.

    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1068523, encodeId=934b106852325, content=已拜读，受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:40:21 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868625, encodeId=7b7d18686251c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 24 20:52:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887339, encodeId=9c6b188e3391c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 12:52:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958859, encodeId=4c0b195885936, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 02 07:52:00 CST 2013, time=2013-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895655, encodeId=3ee31895655f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 28 15:52:00 CST 2013, time=2013-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269433, encodeId=aafa1269433a5, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Feb 19 01:52:00 CST 2013, time=2013-02-19, status=1, ipAttribution=)]
    2021-11-09 湘雅科教

    已拜读，受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1068523, encodeId=934b106852325, content=已拜读，受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:40:21 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868625, encodeId=7b7d18686251c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 24 20:52:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887339, encodeId=9c6b188e3391c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 12:52:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958859, encodeId=4c0b195885936, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 02 07:52:00 CST 2013, time=2013-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895655, encodeId=3ee31895655f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 28 15:52:00 CST 2013, time=2013-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269433, encodeId=aafa1269433a5, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Feb 19 01:52:00 CST 2013, time=2013-02-19, status=1, ipAttribution=)]
    2014-01-24 zhaozhouchifen

    #Cell#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1068523, encodeId=934b106852325, content=已拜读，受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:40:21 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868625, encodeId=7b7d18686251c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 24 20:52:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887339, encodeId=9c6b188e3391c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 12:52:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958859, encodeId=4c0b195885936, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 02 07:52:00 CST 2013, time=2013-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895655, encodeId=3ee31895655f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 28 15:52:00 CST 2013, time=2013-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269433, encodeId=aafa1269433a5, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Feb 19 01:52:00 CST 2013, time=2013-02-19, status=1, ipAttribution=)]
    2013-02-18 guojianrong

    #Meta#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1068523, encodeId=934b106852325, content=已拜读，受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:40:21 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868625, encodeId=7b7d18686251c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 24 20:52:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887339, encodeId=9c6b188e3391c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 12:52:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958859, encodeId=4c0b195885936, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 02 07:52:00 CST 2013, time=2013-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895655, encodeId=3ee31895655f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 28 15:52:00 CST 2013, time=2013-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269433, encodeId=aafa1269433a5, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Feb 19 01:52:00 CST 2013, time=2013-02-19, status=1, ipAttribution=)]
    2013-10-02 维他命

    #CEL#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1068523, encodeId=934b106852325, content=已拜读，受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:40:21 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868625, encodeId=7b7d18686251c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 24 20:52:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887339, encodeId=9c6b188e3391c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 12:52:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958859, encodeId=4c0b195885936, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 02 07:52:00 CST 2013, time=2013-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895655, encodeId=3ee31895655f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 28 15:52:00 CST 2013, time=2013-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269433, encodeId=aafa1269433a5, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Feb 19 01:52:00 CST 2013, time=2013-02-19, status=1, ipAttribution=)]
    2013-04-28 一闲

    #MET#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1068523, encodeId=934b106852325, content=已拜读，受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Nov 09 10:40:21 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868625, encodeId=7b7d18686251c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 24 20:52:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887339, encodeId=9c6b188e3391c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Feb 18 12:52:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958859, encodeId=4c0b195885936, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 02 07:52:00 CST 2013, time=2013-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895655, encodeId=3ee31895655f0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 28 15:52:00 CST 2013, time=2013-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269433, encodeId=aafa1269433a5, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Feb 19 01:52:00 CST 2013, time=2013-02-19, status=1, ipAttribution=)]
    2013-02-19 gao_jian4217

    #肥胖症#

    0

相关资讯

J Pediatr.：促进棕色脂肪燃烧治疗肥胖

科学家已经找到一种可以用来评估脂肪组织功能的新方法，或许可用来对抗肥胖症。当暴露于“冷刺激”时，对头、颈和肩膀部进行热成像扫描可以发现棕色脂肪（BAT）的区域和位置。BAT可以比体内其他类型的脂肪组织产生更多的热量。“如果你拥有更多的BAT，或你的BAT更活跃，则你很可能会消耗更多热量，因此你体内过多的热量或食物就会更少的沉积到白色脂肪组织中去，”该文章的第一作者，来自英国诺丁汉大学的Michae

Cell Metab：棕色脂肪细胞成抗肥胖“战争”新盟友

加州大学旧金山分校提供 在对抗肥胖的战争中，自己的脂肪细胞似乎并不是我们的盟友。但美国加州大学旧金山分校（UCSF）完成的一项新研究表明：普通脂肪细胞经过适当改造也可以用来燃烧热量（卡路里）。 通过研究治疗糖尿病患者的一个普通药物是如何在小鼠体内发挥作用的，加州大学旧金山分校研究团队发现，在男性和小鼠中发现了一种称为PRDM16的蛋白质，该蛋白质可启动脂肪细胞转换过程，即将储存热量的普通的白色